LabCorp

Q1 Results Q/Q Comparison:

  • Revenue increased 5% to $2.4B
    • LabCorp Diagnostics increased 8% to $1.72B
    • Covance Drug Development decreased 2% to $690M
  • GAAP Diluted EPS increased 16% to $1.84
    • Adjusted EPS increased 8% to $2.22
  • Adjusted Operating Income increased 5% to $391M
    • LabCorp Diagnostics increased 11% to $341M
    • Covance Drug Development decreased 19% to $84M
  • Adjusted Operating margin of 16.2%, down from 16.3%
    • LabCorp Diagnostics: 19.9%, up from 19.4%
    • Covance Drug Development: 12.1%, down from 14.7%
  • Quarter-end cash of $366M and debt of $5.9B
  • Lowered 2017 Guidance:
    • Revenue growth of 3.5% to 5.5% (from 4.5% to 6.5%)
    • Adjusted EPS of $9.20 to $9.60 (from $9.35 to $9.75), a year-over-year increase of 4% to 9%

Stock Price: $139
Market Capitalization: $14.3 billion

April 25, 2017

 

 

 


 


 

Menu byMilonic